Skip to content

Nasdaq · CIK 0001819133

TNGX Tango Therapeutics, Inc.

Insider trading from SEC Form 4. Last filing 7 d ago. Close $23.81 on Oct 9, 2026, +233% from the 52-week low and -28% from the high.

Last 90 days

Net insider value
-$1.5M
more sold than bought
Buys
0
$0 by 0 insiders
Sells
3
$1.5M by 2 insiders
Insiders on file
12
with a Form 4 at this company

Price and insider trades, last year

TNGXOct 9, 2026 · close 23.81

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

Open-market buys and sells at Tango Therapeutics, Inc., scored.

ScoreInsiderValueHoldingsPrice contextFiled
18WeakAdam Crystal
President, R&D
sell
$661k
27,000 shares
-19%+254% from low-26% from high
20WeakJessica Newcomb
Principal Accounting Officer
sell
$199k
8,200 shares
-12%+269% from low-22% from high
9WeakAdam Crystal
President, R&D
sell
$604k
27,000 shares
-19%-
37WeakThird Rock Ventures IV, L.P.
owner
sell
$4.0M
500,000 shares
-3%+625% from low0% from high
37WeakThird Rock Ventures IV, L.P.
owner
sell
$2.6M
363,541 shares
-2%+568% from low-24% from high
37WeakThird Rock Ventures IV, L.P.
owner
sell
$5.1M
729,365 shares
-5%+531% from low-34% from high
37WeakThird Rock Ventures IV, L.P.
owner
sell
$2.1M
302,194 shares
-2%+527% from low-34% from high
37WeakThird Rock Ventures IV, L.P.
owner
sell
$7.7M
1,100,000 shares
-7%+533% from low-34% from high
30WeakDouglas Barry
General Counsel
sell
$16k
5,330 shares
-7%-
42ModerateDaniella Beckman
Chief Financial Officer
sell
$25k
8,232 shares
-5%-
36WeakAdam Crystal
See Remarks
sell
$44k
14,283 shares
-8%-
33WeakMace Rothenberg
director
buy
$74k
20,000 shares
+178%-
50ModerateEcoR1 Capital, LLC
owner
sell
$8.4M
2,700,000 shares
-20%-
51ModerateBoxer Capital Management, LLC
other
sell
$9.7M
3,080,000 shares
-46%-
41ModerateBoxer Capital Management, LLC
other
sell
$4.3M
633,000 shares
-9%-
38WeakBoxer Capital Management, LLC
other
sell
$6.1M
875,000 shares
-11%-

Transactions

The last 47 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Oct 1, 2026Adam Crystal
President, R&D
MOption exercise
Common Stock10b5-1
+27,000$5.20$140k142,7437 d ago
Oct 1, 2026Adam Crystal
President, R&D
SOpen-market sale
Common Stock10b5-1
-26,400$24.45$646k116,3437 d ago
Oct 1, 2026Adam Crystal
President, R&D
SOpen-market sale
Common Stock10b5-1
-600$25.32$15k115,7437 d ago
Oct 1, 2026Adam Crystal
President, R&D
MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-27,000$0.00$0233,0407 d ago
Sep 22, 2026Jessica Newcomb
Principal Accounting Officer
SOpen-market sale
Common Stock10b5-1
-700$22.80$16k66,62118 d ago
Sep 22, 2026Jessica Newcomb
Principal Accounting Officer
SOpen-market sale
Common Stock10b5-1
-5,100$23.97$122k61,52118 d ago
Sep 22, 2026Jessica Newcomb
Principal Accounting Officer
SOpen-market sale
Common Stock10b5-1
-2,400$25.17$60k59,12118 d ago
Sep 1, 2026Adam Crystal
President, R&D
MOption exercise
Common Stock10b5-1
+27,000$5.20$140k142,74339 d ago
Sep 1, 2026Adam Crystal
President, R&D
SOpen-market sale
Common Stock10b5-1
-27,000$22.37$604k115,74339 d ago
Sep 1, 2026Adam Crystal
President, R&D
MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-27,000$0.00$0260,04039 d ago
Sep 25, 2025Third Rock Ventures IV, L.P.
owner
SOpen-market sale
Common Stock
-500,000$8.02$4.0M13,863,975Sep 29, 2025
Sep 16, 2025Third Rock Ventures IV, L.P.
owner
SOpen-market sale
Common Stock
-363,541$7.04$2.6M14,363,975Sep 17, 2025
Sep 5, 2025Third Rock Ventures IV, L.P.
owner
SOpen-market sale
Common Stock
-642,906$7.00$4.5M14,813,975Sep 9, 2025
Sep 8, 2025Third Rock Ventures IV, L.P.
owner
SOpen-market sale
Common Stock
-86,459$7.04$609k14,727,516Sep 9, 2025
Aug 22, 2025Third Rock Ventures IV, L.P.
owner
SOpen-market sale
Common Stock
-302,194$7.00$2.1M15,456,881Aug 26, 2025
Aug 19, 2025Third Rock Ventures IV, L.P.
owner
SOpen-market sale
Common Stock
-1,100,000$7.01$7.7M15,759,075Aug 21, 2025
Jun 5, 2025Alexis Borisy
director
AGrant or award
Common Stock
+6,250$0.00$017,500Jun 9, 2025
Jun 5, 2025Lesley Ann Calhoun
director
AGrant or award
Common Stock
+6,250$0.00$012,500Jun 9, 2025
Jun 5, 2025Mace Rothenberg
director
AGrant or award
Common Stock
+6,250$0.00$037,500Jun 9, 2025
Jun 5, 2025John B Ketchum
director
AGrant or award
Common Stock
+6,250$0.00$020,937Jun 9, 2025
Jun 5, 2025Malte Peters
director
AGrant or award
Common Stock
+6,250$0.00$017,500Jun 9, 2025
Jun 5, 2025Mace Rothenberg
director
AGrant or award
Stock Option (Right to Buy)derivative
+37,500$0.00$037,500Jun 9, 2025
Jun 5, 2025Malte Peters
director
AGrant or award
Stock Option (Right to Buy)derivative
+37,500$0.00$037,500Jun 9, 2025
Jun 5, 2025Lesley Ann Calhoun
director
AGrant or award
Stock Option (Right to Buy)derivative
+37,500$0.00$037,500Jun 9, 2025
Jun 5, 2025Alexis Borisy
director
AGrant or award
Stock Option (Right to Buy)derivative
+37,500$0.00$037,500Jun 9, 2025
Jun 5, 2025John B Ketchum
director
AGrant or award
Stock Option (Right to Buy)derivative
+37,500$0.00$037,500Jun 9, 2025
Feb 4, 2025Douglas Barry
General Counsel
SOpen-market sale
Common Stock
-2,774$2.99$8,28968,570Feb 6, 2025
Feb 4, 2025Daniella Beckman
Chief Financial Officer
SOpen-market sale
Common Stock
-4,284$2.99$13k154,232Feb 6, 2025
Feb 4, 2025Adam Crystal
See Remarks
SOpen-market sale
Common Stock
-7,432$2.99$22k165,061Feb 6, 2025
Feb 5, 2025Douglas Barry
General Counsel
SOpen-market sale
Common Stock
-2,556$3.16$8,08166,014Feb 6, 2025
Feb 5, 2025Daniella Beckman
Chief Financial Officer
SOpen-market sale
Common Stock
-3,948$3.16$12k150,284Feb 6, 2025
Feb 5, 2025Adam Crystal
See Remarks
SOpen-market sale
Common Stock
-6,851$3.16$22k158,210Feb 6, 2025
Feb 3, 2025Douglas Barry
General Counsel
AGrant or award
Common Stock
+27,363$0.00$071,344Feb 5, 2025
Feb 3, 2025Daniella Beckman
Chief Financial Officer
AGrant or award
Common Stock
+26,119$0.00$0158,516Feb 5, 2025
Feb 3, 2025Adam Crystal
See Remarks
AGrant or award
Common Stock
+53,015$0.00$0172,493Feb 5, 2025
Feb 3, 2025Daniella Beckman
Chief Financial Officer
AGrant or award
Stock Option (Right to Buy)derivative
+156,713$0.00$0156,713Feb 5, 2025
Feb 3, 2025Adam Crystal
See Remarks
AGrant or award
Stock Option (Right to Buy)derivative
+318,090$0.00$0318,090Feb 5, 2025
Feb 3, 2025Douglas Barry
General Counsel
AGrant or award
Stock Option (Right to Buy)derivative
+164,175$0.00$0164,175Feb 5, 2025
Nov 14, 2024Mace Rothenberg
director
POpen-market purchase
Common Stock
+10,000$3.62$36k21,250Nov 18, 2024
Nov 18, 2024Mace Rothenberg
director
POpen-market purchase
Common Stock
+10,000$3.78$38k31,250Nov 18, 2024
Nov 6, 2024EcoR1 Capital, LLC
owner
SOpen-market sale
Common Stockindirect: See Note
-1,494,558$3.28$4.9M11,836,178Nov 8, 2024
Nov 7, 2024EcoR1 Capital, LLC
owner
SOpen-market sale
Common Stockindirect: See Note
-62,318$3.29$205k11,773,860Nov 8, 2024
Nov 7, 2024EcoR1 Capital, LLC
owner
SOpen-market sale
Common Stockindirect: See Note
-1,143,124$2.92$3.3M10,630,736Nov 8, 2024
Nov 6, 2024Boxer Capital Management, LLC
other
SOpen-market sale
Common Stockindirect: See footnote
-3,080,000$3.14$9.7M3,610,642Nov 7, 2024
Oct 25, 2024Boxer Capital Management, LLC
other
SOpen-market sale
Common Stock
-633,000$6.87$4.3M6,690,642Oct 28, 2024
Oct 21, 2024Boxer Capital Management, LLC
other
SOpen-market sale
Common Stock
-625,000$7.05$4.4M7,573,642Oct 23, 2024
Oct 22, 2024Boxer Capital Management, LLC
other
SOpen-market sale
Common Stock
-250,000$6.78$1.7M7,323,642Oct 23, 2024

Insiders

Everyone who has filed a Form 4 here.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

TNGX insider trading: Tango Therapeutics, Inc. | InsiderTell